Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion announced that it has signed a contract manufacturing and development (CDMO) supply agreement worth approximately KRW 100.0B with TEVA Pharmaceuticals International GmbH for the active pharmaceutical ingredient (API) of the migraine treatment AJOVY®.
📊 [Key Disclosure Details & Financial Highlights]
- Contract Overview
- Contract Type: Other Sales / Supply Contract
- Contract Name: Contract Development and Manufacturing of Active Pharmaceutical Ingredient (API) for Migraine Treatment AJOVY®
- Counterparty: TEVA Pharmaceuticals International GmbH
- Large Scale Company Status: Applicable
- Financial Value & Proportion
- Contract Value: KRW 100,039,802,387 (Approx. KRW 100.0B)
- Recent Annual Sales: KRW 2,176,431,531,380 (Based on 2023 Consolidated Revenue)
- Value relative to Recent Sales: 4.60%
- Contract Term & Dates
- Contract Period: October 21, 2024 ~ July 30, 2025
- Contract Date: October 21, 2024 (Based on Purchase Order approval date)
- Other Important Details
- Contract value is excluding VAT and applied the initial FX rate of USD/KRW 1,371.10 on October 21, 2024.
- The contract amount corresponds to a Purchase Order issued in October 2024.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Contract Execution and Revenue Recognition in Periodic Reports
This disclosure specifies a contract manufacturing supply agreement to be fulfilled over a designated period. Monitoring whether the supply is completed as scheduled without amendments to terms or contract value, as well as tracking its reflection in actual revenue, is important for understanding the practical financial contribution of the contract. Detailed progress can be verified in subsequent disclosures and upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
